Invitation to Presentations of Senzime's Third Quarter 2026 Report
Senzime (SNZZF) will publish its third-quarter 2026 report on October 29, with presentations for investors, analysts and media that day.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senzime (SNZZF) will publish its third-quarter 2026 report on October 29, with presentations for investors, analysts and media that day. The report will be released at 08:00 am CEST. CEO Philip Siberg will present it through a webcast available from 09:00 am CEST on Senzime's investor website.
A live question-and-answer session hosted by Redeye analyst Gustaf Meyer will air on Redeye's platform at 10:00 am CEST. A recording will be published on Redeye's website later the same day.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UPPSALA, SE / ACCESS Newswire / October 26, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime invites investors, analysts, and media to presentations of the third quarter report for 2026 on Oct 29. The report will be published at 08:00 am CEST the same day.
Philip Siberg, CEO of Senzime, will present the Q3 report through a webcast that can be seen from 09:00 am CEST on Senzime's website https://www.senzime.com/investors
A Live Q&A, hosted by Gustaf Meyer, analyst at Redeye, will be aired at 10:00 am CEST via Redeyes platform. A recording of the Q&A will be published later the same day via Redeye's website https://www.redeye.se/company/senzime
Questions for the Q&A interview can be emailed in advance, no later than Oct 29, 10:00 am CEST, to gustaf.meyer@redeye.se
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.
Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.
Attachments
Invitation to presentations of Senzime's third quarter 2026 report
SOURCE: Senzime
View the original press release on ACCESS Newswire